AgingResearch.NewsJoin free

Alcon

CompanyUnited StatesFounded 1945

RORWikidata

Alcon develops 6 assets, the furthest approved (ENCELTO in macular telangiectasia type 2). Mostly small molecule and cell therapy acting on CNTFR, PTGS2 and PTGS1; based in the United States, founded in 1945.

6
Assets
Furthest stage
Approved
13
Trials
6
Signals

Pipeline

6

  • acoltremon

    Activates ocular TRPM8 receptors to stimulate tear production through sensory neural signaling.

    Approved, Small molecule, dry eye syndrome (Phase 3)

  • ENCELTO

    Encapsulated engineered cells secrete ciliary neurotrophic factor to slow retinal photoreceptor loss.

    Approved, Cell therapy, CNTFR, macular telangiectasia type 2

  • Nepafenac Ophthalmic Suspension, 0.3%

    NSAID prodrug inhibiting cyclooxygenase 1 and 2 to reduce ocular inflammation.

    Phase 3, Small molecule, PTGS2, PTGS1, cataract, non-proliferative diabetic retinopathy

3 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms6
  • Trials18
  • Signals7
  • Similar companies6

Papers

Intelligence